News

Meet us at the CPDD 85th Annual Scientific Meeting, Denver, CO, 17th-21st June 2023

DevelRx will be participating in the 85th Annual Scientific Meeting of the College on Problems of Drug Dependence to be held at the Sheraton Denver Downtown Hotel, Denver, Colorado, USA, 17th-21st June, 2023. If you are developing novel centrally-acting compounds and would like to learn more about our services come along and meet us at one of our posters.

Chapter in Mandarin Chinese in book on safety pharmacology

We have recently had our first book chapter published in Mandarin Chinese. The article on abuse and dependence testing procedures is in a book on safety pharmacology that was written to support drug safety evaluations in China and other Asian countries.

Psychedelic drug abuse potential assessment for new drug applications and controlled substance scheduling: A United States perspective

This paper outlines strategies for the non-clinical and clinical evaluation of the abuse potential of psychedelics, ie serotonergic hallucinogens and entactogens for new drug applications to the FDA and scheduling recommendations.

We are pleased to announce new joint DevelRx : URSA-funded PhD studentship with the University of Bath

We are pleased to announce that our application for a 50:50 DevelRx : University Research Studentship Award (URSA) funded PhD studentship with the University of Bath has been accepted.

Novel kappa opioid antagonist lacks opioid agonist properties implicated in opioid-related abuse

If you are developing opioid antagonists for therapeutic use, it is important to use non-clinical studies to profile the effects of the compounds at mu, kappa and delta opioid receptors to confirm mode of action and evaluate the potential for adverse side effects associated with agonist activity at opioid receptors.

New research on kappa opioid receptor activation to be presented at KappaCon 2023

Eloise Kuijer, our PhD student with the University of Bath, will be presenting the results of her research into the effects of activating kappa opioid receptors at KappaCon 2023

Experimental strategies to discover and develop the next generation of psychedelics and entactogens as medicines

Our latest paper describing screening strategies for drug discovery and development to deliver more effective and safer psychedelics and entactogens for clinical use is now available online

Congratulations to David Heal on being elected an Honorary Fellow of the BPS

Congratulations to David Heal on being elected an Honorary Fellow of the British Pharmacological Society for sustained excellence in research, including drug discovery and development

Meet David Heal at the ACNP meeting in Phoenix, December 2022

David Heal will be attending the 61st Annual Meeting of the ACNP (American College of Neuropsychopharmacology), 4th to 7th December 2022, JW Marriott Desert Ridge Resort and Spa, Phoenix, Arizona. If you would like to see David at the ACNP to discuss our consultancy services in the areas of drug abuse evaluation and CNS and metabolic disorders please contact inform@develrx.com.

David Heal contributes to new article 'Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling'

We are pleased to announce that 'Preclinical evaluation of the abuse potential of purified botanical cannabidiol' was the JPET Editor's Choice in July 2022

Congratulations to Eloise Kuijer, our PhD student with the University of Bath, for presentation of a poster at INRC 2022

DevelRx announces publication of book chapter 'New Drugs to treat ADHD: Opportunities and Challenges in Research and Development'

David Heal becomes Scientific Advisor for company developing novel psychedelics

DevelRx to participate in Workshop 'Key considerations in planning, interpreting and reporting animal model studies relevant to psychiatric illness' Join us at the BAP Summer Meeting, London, UK, 24th July 2022

Improving the validity and translation of preclinical research

DevelRx contribute to new publication showing that ulotaront, a novel TAAR1 agonist with 5-HT1A agonist activity, lacks abuse liability and may have potential for the treatment of substance use disorders

Read our comprehensive review about the development of drugs to treat binge-eating disorder

DevelRx and The Canna Consultants raise concerns about the scientifically unjustified, and ethically unacceptable, replicate toxicity testing of cannabidiol demanded by the Food Standards Agency

Sharon Smith joins Editorial Board of Neuropharmacology

We invite you to attend our presentation ‘Psychedelics and CNS Drugs with Novel Mechanisms. Non-clinical Abuse Evaluations to Meet the Challenge’ Continuing Education Course, Virtual SPS Meeting, October 2021

The Next Trip - Developing the Second Generation of Psychedelics and their Analogs for Targeted Medical Use. Watch our podcast on 21st September 2021

Congratulations to Cara Therapeutics and Vifor Pharma on the FDA approval of Korsuva

What are the prospects for new drugs for binge-eating disorder?

DevelRx announces collaboration with Scitegrity

Does every CNS drug-candidate require a program of GLP non-clinical abuse potential testing?

Join us at the 83rd Annual Scientific Virtual Meeting of the CPDD,  21st- 24th June, 2021

How can non-clinical research inform the clinical development and prescribing of psychedelic drugs?

Congratulations to our colleague, Dr Jo Palandri, on her recent publication in the Journal of Psychopharmacology!

How do we adapt to continue making accurate, experimental-based predictions of drug abuse risks?

DevelRx was very pleased to assist Always Pure Organics with the preparation of their three dossiers that were submitted to the FSA last month for Cannabidiol (CBD)-based Novel Foods; one for their Swiss Isolate, one for their Colombian Isolate and one for their Colombian Distillate.

BPS, LASA & Psychiatry Consortium joint workshop: Exploring the Status of Preclinical Models of Psychiatric Disorders - Their Validity and Scope for Successful Translation - 25th February 2021

DevelRx continues its medical education support for psychiatrists and other healthcare providers treating attention deficit hyperactivity disorder.

Professor David Heal will be co-presenting two posters at the American College of Neuropsychopharmacology (ACNP) 59th Annual Meeting - Virtual Conference to be held from 6th to 9th December, 2020.

Professor David Heal, Dr Sharon Smith and Dr Reem Elbekai will be co-presenting two posters on Centanafadine at the American College of Toxicology (ACT) Virtual Meeting (November 12th to 19th 2020).

DevelRx is delighted to announce that the University of Bath and DevelRx have agreed to co-sponsor a PhD project entitled “Mu and kappa opioid receptors in addictive behaviour”.

David Heal will give a presentation at the American College of Toxicology Virtual Meeting (November 12th to 19th 2020) as part of the Continuing Education Course—CE07 entitled “Understanding the Assessment of Abuse Potential: Industry and Regulatory Perspective”